X2.2.2 Systemic corticosteroids for treatment of exacerbations

Systemic corticosteroids reduce the severity of and shorten recovery from exacerbations (Walters 2014) [evidence level I, strong recommendation].

Walters et al report that there is high-quality evidence that systemic corticosteroids reduce treatment failure (defined as additional treatment, hospital admission/re-admission for index episode, return to emergency department, unscheduled physician visit for the index episode), improve lung function, shorten recovery and reduce the severity of exacerbations of COPD (Walters 2014) [evidence level I]. Systemic corticosteroids reduced the risk of treatment failure by over half compared with placebo in nine studies (n = 917) with median treatment duration 14 days, odds ratio (OR) 0.48 (95% CI 0.35 to 0.67. The number needed to treat to avoid one treatment failure is 9. There is no evidence that treatment with corticosteroids alters mortality.

Unlike earlier reviews this review included four papers that compared intravenous corticosteroids with oral corticosteroids and two papers with ventilated patients in ICU. In patients requiring ventilation in ICU, pooled data did not show a reduction in length of stay, duration of ventilation or mortality in those receiving corticosteroids compared with placebo (Walters 2014). Walters et al concluded that there is no evidence of benefit for intravenous treatment compared with oral treatment with corticosteroids on treatment failure, relapse or mortality. Hyperglycaemia rates were higher with intravenous corticosteroids.

With regards to duration of treatment, a meta-analysis by Walters et al (Walters 2018) concluded that five days of oral corticosteroids is likely to be sufficient.

In summary, a 5 day course of oral prednisolone of 30mg to 50mg is adequate. In patients who have been on oral corticosteroids for longer than 14 days, tapering may be necessary. Patients on long-term oral corticosteroid therapy (> 7.5 mg prednisolone daily for more than 6 months) are at risk of developing osteoporosis. Prevention and treatment of corticosteroid-induced osteoporosis should be considered.

There is emerging evidence that blood eosinophil levels can be used as a biomarker to determine which patients require oral corticosteroids for exacerbations of COPD.  A small, single centre, double blind randomised controlled trial used blood eosinophils as a biomarker to determine if prednisolone would be given for an exacerbation of COPD.  In the intervention arm, only patients with blood eosinophils above 2% received prednisolone.  In the standard arm, all patients received prednisolone.   The prednisolone dose was 30mg for 14 days and both groups received oral antibiotics.  There was no difference in treatment failure or health status between the biomarker and standard groups (Bafadhel 2012). Bafadhel re-analysed data from 3 additional randomised controlled trials that examined the use of oral corticosteroids in COPD exacerbations (n=243) (Bafadhel 2014). Patients had blood eosinophil levels measured at the time of COPD exacerbation. Blood eosinophils >2% were a useful biomarker to determine which patients benefit from systemic corticosteroids. The trial designs had considerable heterogeneity. Further, larger studies with long term follow up are required before any firm recommendations can be made.